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The relevance of cerebrospinal fluid
α-synuclein levels to sporadic and
familial Alzheimer’s disease
Daniel Twohig1, Elena Rodriguez-Vieitez2, Sigrid B. Sando3,4, Guro Berge4, Camilla Lauridsen4, Ina Møller3,
Gøril R. Grøntvedt3,4, Geir Bråthen3,4, Kalicharan Patra1, Guojun Bu5, Tammie L. S. Benzinger6, Celeste M. Karch7,
Anne Fagan8, John C. Morris8, Randall J. Bateman8, Agneta Nordberg2,9, Linda R. White3,4,
Henrietta M. Nielsen1* and for the Dominantly Inherited Alzheimer Network (DIAN)

Abstract
Accumulating evidence demonstrating higher cerebrospinal fluid (CSF) α-synuclein (αSyn) levels and αSyn
pathology in the brains of Alzheimer’s disease (AD) patients suggests that αSyn is involved in the pathophysiology
of AD. To investigate whether αSyn could be related to specific aspects of the pathophysiology present in both
sporadic and familial disease, we quantified CSF levels of αSyn and assessed links to various disease parameters in a
longitudinally followed cohort (n = 136) including patients with sporadic mild cognitive impairment (MCI) and AD,
and in a cross-sectional sample from the Dominantly Inherited Alzheimer’s Network (n = 142) including participants
carrying autosomal dominant AD (ADAD) gene mutations and their non-mutation carrying family members.
Our results show that sporadic MCI patients that developed AD over a period of two years exhibited higher
baseline αSyn levels (p = 0.03), which inversely correlated to their Mini-Mental State Examination scores, compared
to cognitively normal controls (p = 0.02). In the same patients, there was a dose-dependent positive association
between CSF αSyn and the APOEε4 allele. Further, CSF αSyn levels were higher in symptomatic ADAD mutation
carriers versus non-mutation carriers (p = 0.03), and positively correlated to the estimated years from symptom
onset (p = 0.05) across all mutation carriers. In asymptomatic (Clinical Dementia Rating < 0.5) PET amyloid-positive
ADAD mutation carriers CSF αSyn was positively correlated to 11C-Pittsburgh Compound-B (PiB) retention in several
brain regions including the posterior cingulate, superior temporal and frontal cortical areas. Importantly, APOEε4positive ADAD mutation carriers exhibited an association between CSF αSyn levels and mean cortical PiB retention
(p = 0.032). In both the sporadic AD and ADAD cohorts we found several associations predominantly between CSF
levels of αSyn, tau and amyloid-β1–40.
Our results suggest that higher CSF αSyn levels are linked to AD pathophysiology at the early stages of disease
development and to the onset of cognitive symptoms in both sporadic and autosomal dominant AD. We conclude
that APOEε4 may promote the processes driven by αSyn, which in turn may reflect on molecular mechanisms linked to
the asymptomatic build-up of amyloid plaque burden in brain regions involved in the early stages of AD development.
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Introduction
Intracellular neurofibrillary tau tangles and extracellular
amyloid-β (Aβ) plaques are the main neuropathological
hallmarks of Alzheimer’s disease (AD), however, at autopsy more than 50% of these patients exhibit concurrent
α-synuclein (αSyn) pathology [1, 16, 31]. Conversely, it
has been shown that Aβ plaques promote the development of cortical αSyn lesions in individuals with Parkinson’s disease (PD), and up to 50% of PD with dementia
patients develop Aβ and tau pathology sufficient for a secondary pathological diagnosis of AD [19, 46]. α-synuclein,
a 140 amino-acid protein encoded by the SNCA gene, is
abundantly expressed neuronal presynaptic terminals [20].
The peptide corresponding to residues 61–95 of αSyn was
originally discovered 25 years ago in Aβ plaques and
named the non-Aβ component (NAC) [58]. Follow-up
studies from the same group further demonstrated NAC
immune-reactivity in diffuse Aβ plaques which may result
in the formation of mature compact Aβ plaques [33]. Results from these studies suggest that αSyn might be involved in the development of AD from the very early
stages of Aβ pathology formation. In support, a recent
study demonstrated a positive correlation between cerebrospinal fluid levels of αSyn and Aβ plaque deposition in
cognitively normal individuals with subjective memory
complaints. The authors speculated that CSF αSyn levels
may be related to pathophysiological mechanisms occurring early in the preclinical phase of AD [59].
The relevance of correlating αSyn levels in the CSF to
brain parenchymal concentration of αSyn in AD patients
is nevertheless controversial due to the lack of autopsyvalidated studies assessing αSyn levels in paired CSF and
brain tissue samples. Ideally, advancements in radiotracer
chemistry could allow for ante-mortem imaging studies in
which CSF αSyn concentrations could be correlated to
αSyn load in the antemortem brain, similar to PiB-PET
correlations between CSF Aβ levels and brain amyloid
plaque load [13]. Hence the exact relationship between
the low CSF αSyn and brain parenchymal Lewy bodies as
occurring in patients with synucleinopathies like PD [68]
and dementia with Lewy bodies (DLB) [37] remains unknown. Similarly, the relevance of slightly increased CSF
αSyn levels in AD patients [26] to αSyn pathology in the
brain is also unclear.
In a study of brains from AD patients devoid of Lewy
bodies, intracellular levels of soluble monomeric αSyn
were two-fold higher than in controls and significantly
correlated to cognitive decline [28]. Potential alterations
of CSF αSyn levels in the same subjects were not investigated. Although αSyn can interact with a multitude of
cellular components, of which many have been shown to
potentially contribute to neurodegeneration [66], the
molecular underpinnings of these findings in relation to
the development of AD remain poorly understood.
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Results from studies of the AD mouse model Tg2576
crossed onto an SNCA knockout background proposed
that loss of αSyn increased the Aβ plaque load in all forebrain areas by the age of 18 months [23]. In support, it
was found that αSyn inhibited amyloid plaque formation
in APPPS1 mice co-expressing the SNCA gene. The authors of the same study further demonstrated that the
seeding activity of injected Aβ containing brain homogenates was reduced, and that Aβ deposition was suppressed
in grafted tissue from the [A30P]aSYN transgenic mouse
model [2]. The mechanisms underlying the inverse association between Aβ plaque formation and αSyn have yet to
be determined, and may be complicated by the existence
of various αSyn species (monomers, oligomers, fibrils)
which individually may have differing effects on AD
pathophysiology. For example, Larson et al. recently reported that increasing oligomeric αSyn selectively decreased presynaptic proteins and cognitive performance in
the bigenic J20xTgI2.2 AD mouse model where both
monomeric and oligomeric αSyn increase with age, [27].
In addition to the overlapping neuropathological features between AD and synucleinopathies like PD and
DLB, but not multiple system atrophy [42], these disorders also share the APOEε4 allele as a strong genetic risk
factor. The APOEε4 allele increases the risk of AD by up
to 15-fold and the risk of DLB by up to 6-fold [7, 10].
Furthermore, the APOEε4 allele also increases the risk of
PD and decreases the age of disease onset [30]. The
exact molecular pathways underlying the increased risk
of several neurodegenerative disorders in APOEε4-carriers have yet to be identified but the urgency to do so is
clearly illustrated by the rather high frequency (~ 14%)
of this allele in the normal population [32].
In the current study we aimed to assess the pathophysiological relevance of αSyn levels in CSF to the development of AD, including surrogate markers of AD
neuropathology, in a clinical setting. We further aimed
to investigate potential effects of the APOEε4 risk allele
on identified relationships. For our purposes we used
two cohorts, a longitudinally followed cohort of patients
with sporadic MCI and AD to investigate potential relationships between αSyn and disease progression. The
second cohort was comprised of a cross-sectional sample from the Dominantly Inherited Alzheimer’s Disease
Network (DIAN) including participants with autosomal
dominant mutations in the APP, PSEN1 and PSEN2
genes causing early-onset autosomal dominant Alzheimer’s disease (ADAD), and their non-mutation carrying
relative control participants [3]. The latter cohort was
included to enable specific analyses of relationships between αSyn and the development of symptoms in subjects that will de facto develop Alzheimer’s disease.
Furthermore, inclusion of subjects with ADAD mutations also enabled us to assess potential associations
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between CSF αSyn levels and specific mutations in the
genes encoding key components in the Aβ peptide production pathway i.e. the amyloid precursor protein
(APP) and the presenilins 1 and 2 (PS1 and PS2).

Materials and methods
Study participants

Subjects from two different cohorts were included in the
present study. The longitudinally followed cohort totaling n = 136 subjects, including n = 52 subjects that were
cognitively healthy controls and n = 84 patients who at
baseline were diagnosed with sporadic MCI (n = 57) or
AD (n = 27). Clinical diagnoses of MCI or AD were
based on the International Working Group on Mild
Cognitive Impairment Criteria [63] and the National Institute of Neurological and Communicative Disorders
and Stroke and the Alzheimer’s Disease and Related Disorders Association criteria [34, 35]. The clinical workup
and results from parts of this cohort were previously reported [5, 6, 45]. Briefly, consenting participants were recruited by the Department of Neurology at Trondheim
University Hospital in Trondheim, Norway on the conditions that individuals had adequate vision and hearing,
did not exhibit high alcohol consumption or use of
anti-coagulation medication, and had no psychiatric or
malignant disease. Cognitively healthy control subjects
were recruited from elderly caregivers who were not
genetically related to the patients or from societies for
retired people in central Norway. Cerebrospinal fluid
was drawn at baseline and at intervals of 12-months
follow-up examinations over two years. Control individuals had their CSF sampled at baseline only, due to restrictions pertaining to ethical permits; however, they
were clinically assessed both at baseline and at the
study-end. Cerebrospinal fluid sampling and CSF AD
biomarker analysis (for research purposes only) including quantification of Aβ1–40, Aβ1–42, total tau (t-tau) and
tau phosphorylated at Thr181 (p-tau) levels were previously described [6]. Both patient and control groups
were APOE genotyped from blood samples and underwent cerebral volumetric 3-Tesla MRI (3T-MRI) brain
imaging at baseline and after two years. Upon completion of the study, MCI patients were re-classified into
two groups based on their baseline and two-year
follow-up diagnoses. Patients diagnosed with MCI at
baseline and who remained diagnosed with MCI after
two years were classified as MCI-MCI (n = 30), while patients who were MCI at baseline but that fulfilled the
clinical criteria for AD after two years were classified as
MCI-AD (n = 27). The studies performed on this cohort
were approved by the regional ethics committee in
Trondheim, Norway (2010/226) and Stockholm, Sweden
(2016/771–31/4) and carried out in agreement with the
Helsinki Declaration.
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Participants in the second cohort were a cross-sectional
sample from the multi-site Dominantly Inherited Alzheimer’s
Network (DIAN) (https://dian.wustl.edu/our-research/observational-study/). The DIAN registry includes mutation carrying and non-mutation carrying adult biological children from
families in which one parent carries an ADAD causative mutation in the APP, PSEN1 or PSEN2 genes. At inclusion, and
during subsequent visits, DIAN participants were assessed
neuropsychologically, biochemically (CSF and plasma), and
underwent structural neuroimaging using 3T-MRI, and functional neuroimaging using PET combined with either fluorodeoxyglucose (FDG-PET) or PiB to quantify brain glucose
metabolism and Aβ deposition respectively [4]. Updated
datasets are generated biannually in what are termed dataset
“freezes”. For the current study we examined subjects from
the DIAN dataset freeze-10 including a total of n = 92
ADAD mutation carriers: n = 24 APP, n = 50 PSEN1,
and n = 18 PSEN2 mutation carriers, as well as n = 50
non-mutation carriers who were genetically related to the
mutation carriers but did not harbor ADAD mutations. Included subjects were considered as symptomatic if fulfilling
the criteria for a Clinical Dementia Rating (CDR) score ≥
0.5. The purposes of the current study involving DIAN participants were approved by the local ethics committee in
Stockholm, Sweden (2016/2114–31/4) and the study was
carried out in agreement with the Helsinki Declaration.
αSyn quantification

Quantification of CSF αSyn in samples from both cohorts was performed using a commercially available
sandwich enzyme-linked immunosorbent assay (ELISA)
(AnaSpec; California, USA) according to the manufacturer’s instructions and using overnight incubation at 4 °C
for the sample incubation step. Samples were assayed
alongside freshly prepared standard curves for each individual assay. Standards, study subject and internal control
samples were run in duplicates and averaged. Spike recovery experiments were performed to assess matrix effects
by adding known concentrations of the supplier-provided
αSyn standard to diluted CSF resulting in a spike recovery
range of 99–122%. Intra- and inter-assay coefficients of
variation were determined by repeated analysis of pooled
CSF samples as internal controls resulting in coefficients
of variation of < 15% respectively for the two lots of assays
used to quantify αSyn in the two cohorts.
DIAN participant MRI image acquisition

Structural MRI acquisition was performed using the Alzheimer Disease Neuroimaging Initiative (ADNI) protocol
[21, 22]. Participating sites were required to pass initial
and regular follow-up quality control assessments to
insure acquisition conformity. Each participant received
an accelerated 3D sagittal T1-weighted MPRAGE on a
3T scanner. A high quality, whole-brain image with
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1.1 × 1.1 × 1.2 mm voxels was acquired in approximately
5–6 min. Before further image processing, images were
screened for artifacts and protocol compliance by the
ADNI imaging core.
DIAN participant PET image acquisition and processing

A subset of n = 132 ADAD participants (mutation carriers n = 85, non-mutation carriers n = 47) underwent
PiB-PET imaging. Each site underwent an initial evaluation to ensure compliance with common PiB-PET
ADNI protocols. Amyloid imaging was performed with a
bolus injection of ∼15 mCi of PiB. Dynamic acquisition
consisted of either a 70-min scan starting at injection or
a 30-min scan beginning 40 min post injection. For analysis, the PiB-PET data within the common time frame
between 40 and 70 min was used. The ADNI PET Core
verified that all PET images were acquired using the
established protocol and substantially free of artifacts.
Each subject’s PET data were motion-corrected and
registered to their MRI using methods described in detail elsewhere [11, 49]. For each participant, the
T1-weighted MRI image was segmented into grey and
white matter tissue maps. An inclusive binary gray matter mask was subsequently applied to the resulting atlas
to obtain individual gray matter atlases. An automated
quantitative image analysis approach was applied using
regions of interest generated with FreeSurfer [14] using
an in-house software previously described [36, 40, 54]. A
regional spread function based approach for partial volume correction of PET data was subsequently implemented using FreeSurfer regions [48] to generate partial
volume corrected regional PET data. Partial volume corrected PiB data were used to quantify PiB retention, as it
was demonstrated to produce accurate results [53].
Regional partial volume corrected PiB retention data
was evaluated in all FreeSurfer regions of interest in
Standardized Uptake Value Ratio (SUVR) units, using
the brainstem as reference, as this was reported as
optimum quantification procedure for PiB-PET in DIAN
studies [53]. Overall brain PiB retention was given by
the mean cortical PiB retention, calculated as the average PiB SUVR across four cortical regions (prefrontal,
gyrus rectus, lateral temporal, and precuneus) as previously used [44]. In addition, exploratory analyses were
performed across forty-two bilateral regions of interest
from the FreeSurfer atlas. PiB positivity was defined by a
mean cortical SUVR uptake using partial volume corrected data and the brainstem as reference region ≥0.72
cutoff value, equivalent to an SUVR of ≥1.42 if using the
cerebellar grey matter, as previously described [56].
Statistics

Normal distribution of the data was assessed by use of
the Shapiro-Wilk test. Accordingly, statistical tests
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applied for cross-sectional group comparisons were either
non-parametric (Kruskal-Wallis tests followed by pairwise
comparisons with the Mann-Whitney U test) or parametric
(analysis of variance [ANOVA] or analysis of covariance
[ANCOVA] with age entered as covariate when relevant,
followed by pairwise comparisons when appropriate, performed with the Student’s t-test). The Bonferroni correction
was applied to account for multiple comparisons.
In the longitudinal cohort, CSF αSyn levels did not follow
a normal distribution and were therefore log-transformed
to achieve normal distribution of the data for which parametric tests were used. Longitudinal changes were assessed
using the repeated measures multivariate analysis of
variance (MANOVA) approach, and correlation analyses were performed by use of the Spearman’s rank
correlation test on non-log-transformed data. Data is
presented as mean ± standard deviation or as median with
range (min-max). A p-value of ≤0.05 was considered statistically significant.
In order to compare CSF αSyn levels between subjects
with AD pathological versus non-pathological CSF AD
biomarker levels receiver operating characteristic (ROC)
curve analyses were performed for the longitudinal cohort using the clinical status (cognitively healthy controls versus a baseline AD diagnosis) as the dichotomous
variable to establish biochemical cutoff values. Cutoff
values were determined based on the highest Youden
index defined as sensitivity + specificity − 1.
In the DIAN cohort, CSF αSyn levels did not follow a
normal distribution hence we log-transformed the data so
that the association between αSyn with estimated years
from symptom onset (EYO) was evaluated using the Pearson’s correlation test. For brain PiB-PET imaging-related
CSF αSyn analyses, linear regression was applied to predict regional PiB-retention as a function of CSF αSyn and
EYO as independent variables, separately in ADAD mutation carriers and non-mutation carriers. The same linear
regression model was applied after mutation carriers were
stratified into asymptomatic (CDR < 0.5) and symptomatic
(CDR ≥ 0.5) mutation carriers, as well as for the subset of
PiB-positive asymptomatic mutation carriers. Additionally,
in mutation carriers the interaction of αSyn and APOEε4
status (positive/negative) was investigated to elucidate
whether the relationship of regional PiB retention and
αSyn is influenced by APOEε4 status. Finally, regional PiB
retention was modeled as a function of αSyn and EYO
separately in APOEε4-positive and APOEε4-negative mutation carriers.
All statistical analyses concerning CSF αSyn levels and
their association to parameters unrelated to brain imaging
were performed in JMP software v.12.1.0 (SAS Institute
Inc.). Statistical analyses regarding associations between CSF
αSyn and amyloid PET data in the DIAN cohort were performed using the R v.3.1.0 software (The R Foundation for
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Statistical Computing, http://www.r-project.org/). Graphical
representations of significant linear associations were obtained with the ggplot2 package v.1.0.1, as implemented in
R. The significance level for all statistical tests and models
was set at p ≤ 0.05. On the brain volumes, display of regression standardized β coefficients of the significant associations between CSF αSyn and regional PiB-PET were
performed using BrainNet viewer [67] (http://www.nitrc.org/projects/bnv/) implemented in MATLAB.

Results
Descriptive statistics of the longitudinally followed cohort
of sporadic patients

The demographics and clinical characteristics of the longitudinal cohort were in part previously published [45]
and are shown in Table 1. The control group was significantly older than the MCI and AD patient groups, thus
age was added as a covariate when including control
subjects in the statistical analyses. At the two-year
follow-up 48% of the subjects diagnosed with MCI at
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baseline had progressed to an AD diagnosis (MCI-AD),
whereas 52% remained stable (MCI-MCI). The patient
dropout rate at 24-months was 17% of the MCI-MCI
patients, 7% of the MCI-AD patients, and 15% of the
AD patients. As expected, the Mini-Mental State
Examination (MMSE) scores differed significantly
amongst the investigated groups with AD patients displaying the lowest scores (p < 0.001). In comparison to
controls all individual patient groups exhibited altered
levels of CSF AD biomarkers including Aβ1–42, Aβ1–40,
Aβ42/40, t-tau and p-tau. A much lower frequency of
APOEε4 carriers was observed in the control group
(38%) compared to the MCI (66%) and AD patient
groups (82%) (p < 0.001).
Higher baseline CSF αSyn levels in MCI patients
converting to sporadic AD

We first sought to compare CSF αSyn levels between
the diagnostic groups. At baseline, MCI patients that
after 24 months fulfilled the criteria for an AD diagnosis

Table 1 Longitudinal cohort baseline characteristics
MCI
All

MCI-MCI

MCI-AD

N

57

54

27

27

27

Sex (% f/m)

65/35

53/47

44/56

59/41

52/48

-d

Age at examination (yrs)a

68 ± 5

65 ± 6

66 ± 6

64 ± 4

64 ± 6

** e

MMSE

30 (28–30)

28 (23–30)

28 (25–30)

27 (23–29)

23 (16–27)

*** f

APOEε4 carrier (%)

38 (n = 55)

66

63

74

81

*** d

CSF

969.7

546.5

574.3

539.0

476.8

*** f

Aβ1–42

(500–1674)

(173–1269)

(173–1269)

(283–1060)

(212–1092)

(pg/mL)b

(n = 45)

CSF

17.1

13.5

12.9

14.2

14.9

(11–41)

(4–31)

(4–31)

(8–23)

(7–29)

b

Aβ1–40
b

(ng/mL)
CSF
Aβ42/40

b

(n = 41)

(n = 26)

(n = 23)

(n = 26)

0.059

0.042

0.049

0.039

0.034

(0.013–0.096)

(0.008–0.118)

(0.008–0.118)

(0.012–0.088)

(0.007–0.080)

(n = 26)

(n = 23)

(n = 26)

(n = 41)
CSF
t-tau
b

Alzheimer’s
disease

p-valuec

Controls

269.0

447.9

315.2

550.8

624.2

(138–1314)

(99–2325)

(99–1057)

(163–2325)

(177–1540)

(pg/mL)

(n = 46)

CSF

53.5

69.9

53.0

85.6

90.8

p-tau

(33–135)

(16–169)

(16–131)

(37–169)

(28–157)

(pg/mL)b

(n = 46)

** f

*** f

*** f

*** f

MCI = mild cognitive impairment MCI-MCI = MCI patients who remained MCI at the 24-month follow up
MCI-AD = MCI patients who converted to Alzheimer’s disease at the 24-month follow up
MMSE = Mini-Mental State Examination score
a = mean ± standard deviation b = median (minimum-maximum)
c = P-value reflecting potential differences between the groups Controls, mild cognitive impairment and Alzheimer’s disease d = χ2 test e = one-way ANOVA
f = Kruskal-Wallis test - = non-significant
** = p ≤ 0.01 *** = p ≤ 0.001
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(MCI-AD) exhibited the highest CSF αSyn levels compared
to controls (Fig. 1a), while CSF αSyn levels did not significantly differ between controls and the non-converting MCI
patients (MCI-MCI), and the AD group (Fig. 1a). No differences in CSF αSyn levels were noted between the patient
groups at either the 12-month (Fig. 1b) or 24-month
(Fig. 1c) follow-ups.
Association between APOEε4 and higher CSF αSyn levels
in sporadic AD patients

As APOEε4 is a common genetic risk factor for both synucleinopathies and AD [7, 10, 30], we assessed the effect of
APOEε4 on CSF αSyn levels. Within the MCI patient group
APOEε4 carriers exhibited higher αSyn levels compared to
non-carriers at the 24-month follow up (Fig. 2c). Additionally, MCI-AD APOEε4 carriers exhibited higher CSF αSyn
than non-carriers at the 12-month (Fig. 2e) and 24-month
(Fig. 2f) follow-ups. The MCI-AD APOEε4 carrying patient
group also exhibited significantly higher CSF αSyn levels at
baseline compared to APOEε4 carrying MCI-MCI patients
and controls (Fig. 3a), while no differences in CSF αSyn were
found at the 12-month follow up (Fig. 3b). However, at
24-months MCI-AD APOEε4 carriers again had higher CSF
αSyn than MCI-MCI APOEε4 carriers (Fig. 3c). This difference in CSF αSyn levels was absent when comparing
APOEε4 non-carrier patient groups at any time point
(Fig. 3d-f ). Intriguingly, the elevated CSF αSyn levels
found in MCI-AD patients exhibited a dose-dependent
relationship with the APOEε4 allele at all three time
points (Fig. 4a-c).
To assess any longitudinal changes in CSF αSyn levels
occurring within- or between the patient groups we performed repeated measures MANOVAs spanning the intervals of: baseline to 12-months, baseline to 24-months,
and 12-months to 24-months (Fig. 5). When all patients

a

b
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(diagnosed with MCI or AD at baseline) were grouped
as either APOEε4 carriers or non-carriers, APOEε4 carriers showed increasing CSF αSyn levels (+ 17%) from
baseline to 12-months, followed by a decrease (− 10%)
from 12- to 24-months (Fig. 5a). Patients that did not
carry the APOEε4 variant consistently exhibited a longitudinal decline in CSF αSyn levels which reached statistical significance between the 12- and 24-months
examinations (Fig. 5a), thus proposing potentially different pathological processes for APOEε4 carriers versus
non-carriers. These findings prompted us to also subdivide the MCI-AD patient group into APOEε4 carriers or
non-carriers. We found a significant increase in CSF
αSyn (+ 5%) in MCI-AD APOEε4 carriers from baseline
to 12-months, while also observing elevated CSF αSyn in
MCI-AD APOEε4 carriers versus non-carriers from 12to 24-months (Fig. 5b). Moreover, when the MCI-AD
patient group was further subdivided by APOEε4 zygosity
we found significant differences in CSF αSyn levels from
baseline to 12-months, and 12- to 24-months (Fig. 5c). A
significant difference between APOEε4 homozygotes,
heterozygotes, and non-carriers was also found in the AD
group between 12-months and 24-months (data not
shown).
Links between CSF αSyn, AD biomarkers and cognition in
sporadic patients

In the absence of established brain imaging tools to assess ante-mortem αSyn burden in the brain, we assessed
potential correlations between CSF αSyn levels and
established fluid surrogate markers of AD pathology and
global cognitive test scores. At baseline, 12-months, and
24-months CSF αSyn showed a positive correlation to
CSF Aβ1–40, t-tau, and p-tau in all patient groups and
controls (Table 2). All MCI patients showed a marked

c

Fig. 1 CSF αSyn levels in sporadic MCI and Alzheimer’s disease cohort. Quantification of CSF αSyn levels at (a) baseline, (b) 12-months and (c) 24-months in
the four longitudinally diagnosed patient groups: control = cognitively healthy controls, MCI-MCI = MCI patients who remained MCI at the 24-month follow
up, MCI-AD = MCI patients who converted to Alzheimer’s disease at the 24-month follow up, AD = patients diagnosed with AD at baseline. P-values were
calculated using a one-way ANCOVA of log-transformed data with age entered as a covariate with post-hoc testing by use of the student’s t-test. Bonferroni
correction was used to account for multiple comparisons (a: n = 6 comparisons, b-c: n = 3 comparisons). Results are displayed without log-transformation or
age-correction (raw data)
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a

b

c

d

e

f

Fig. 2 CSF αSyn measured in APOEε4-positive versus APOEε4-negative sporadic MCI patients. a-c CSF αSyn quantified in MCI patients at baseline,
12- and 24-months respectively. APOEε4-positive patients are shown as grey shaded boxes, APOEε4-negative patients are white boxes. Orange
data points represent patients longitudinally diagnosed as MCI-AD, brown points represent MCI-MCI patients. d-f CSF αSyn quantified in MCI-AD
diagnosed patients at baseline, 12- and 24-months respectively. P-values were calculated using the one-way ANCOVA of log-transformed data,
with age entered as a covariate with post-hoc testing by use of the student’s t-test. Results are displayed without log-transformation or agecorrection (raw data). MCI-AD = MCI patients who converted to Alzheimer’s disease at the 24-month follow up

strengthening in the correlations of CSF αSyn to CSF
Aβ1–40, t-tau, and p-tau between baseline and 12-months,
and were the strongest in the MCI-AD group compared to
all other groups at 12-months (Table 2). In MCI-MCI patients the correlations of CSF αSyn to CSF Aβ1–40 and
p-tau strengthened from baseline to 24-months, while the
MCI-AD group exhibited the strongest correlation between
CSF αSyn and t-tau (all above Spearman’s ρ = 0.9 respectively) (Table 2). The AD group exhibited a modest increase
in the correlations between CSF αSyn and CSF t-tau and
p-tau between baseline and 12-months, but showed weakening of the correlation between CSF αSyn and Aβ1–40 over
the same time interval. Additionally, at 24-months the AD
group was the only group of patients at any time point to
exhibit a significant correlation between CSF αSyn and
Aβ1–42. At 24-months however, the AD group exhibited the
weakest correlations between CSF αSyn and the CSF AD
biomarker panel. Intriguingly, our analyses revealed a

significant association between CSF αSyn levels and
cognition, in which higher CSF αSyn levels were significantly
correlated to lower MMSE scores in the MCI-AD group at
baseline (Table 2); moreover, the correlation was solely attributable to APOEε4 carrying MCI-AD patients (ρ=-0.607,
p=0.005) (non-carrier ρ=-0.618, p=0.140).
αSyn levels in sporadic patients with or without
pathological CSF AD biomarkers

The MCI and AD patients enrolled in the longitudinal cohort were diagnosed according to clinical guidelines [34,
63] without workup of CSF AD biomarkers to support the
clinical diagnosis, however, for research purposes the CSF
biomarkers were assessed. With the rationale to compare
CSF αSyn levels between patients with pathological
versus without pathological CSF AD biomarker levels,
we employed ROC analyses to produce cutoffs for the
core CSF AD biomarkers Aβ1–42, t-tau, p-tau and the
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Fig. 3 CSF αSyn measured in the subjects of the longitudinal cohort based on APOEε4 status. a-c APOEε4-positive (grey boxes) subjects examined
at baseline, 12- and 24-months respectively. d-f APOEε4-negative patients examined at baseline, 12- and 24-months respectively. P-values were
calculated using the one-way ANCOVA of log-transformed data, with age entered as a covariate with post-hoc testing by use of the student’s t-test.
Bonferroni correction was used to account for multiple comparisons (a: n = 6 comparisons, b-f: n = 3 comparisons). Results are displayed
without log-transformation or age-correction (raw data). MCI-MCI = MCI patients who remained MCI at the 24-month follow up, MCI-AD = MCI
patients who converted to Alzheimer’s disease at the 24-month follow up, AD = patients diagnosed with Alzheimer’s disease at baseline

a

b

c

Fig. 4 Cerebrospinal fluid αSyn levels in MCI-AD patients at: a baseline (non-carrier n = 7, heterozygous n = 9, homozygous n = 11), b 12-months
(non-carrier n = 7, heterozygous n = 8, homozygous n = 11), and c 24-months (non-carrier n = 7, heterozygous n = 8, homozygous n = 9). P-values
are presented first as uncorrected followed by Bonferroni corrected (a-c: n = 3 comparisons). In a P-values were calculated using the non-parametric
Kruskal-Wallis with post-hoc testing by use of the Mann-Whitney U test. Bonferroni correction was used to account for multiple comparisons. In (b-c)
P-values were calculated using the one-way ANCOVA with age entered as a covariate with post-hoc testing by use of the student’s t-test. Results are
displayed without age-correction (raw data). MCI-AD = MCI patients who converted to Alzheimer’s disease at the 24-month follow up
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Fig. 5 Longitudinal assessment of mean CSF αSyn values at baseline, 12-months and 24-months in (a) a pooled MCI and Alzheimer’s disease
(AD) patient group classified as either APOEε4 carriers (baseline to 12-months n = 58, 12-months to 24-months n = 47) or non-carriers (baseline to
12-months n = 21, 12-months to 24-months n = 19). b the MCI-AD patient group classified as either APOEε4 carriers (baseline to 12-months n = 19,
12-months to 24-months n = 16) or non-carriers (baseline to 12-months n = 7, 12-months to 24-months n = 7), c the MCI-AD patient group
classified as either APOEε4 non-carriers (baseline to 12-months n = 7, 12-months to 24-months n = 7), heterozygotes (baseline to 12-months n = 8,
12-months to 24-months n = 7) or homozygotes (baseline to 12-months n = 11, 12-months to 24-months n = 9). P-values within patient groups
over 1-year intervals are shown in red along the trend lines, and between-group p-values are indicated in black. P-values were calculated using
repeated measures MANOVA analysis of log-transformed data. MCI-AD = MCI patients who converted to Alzheimer’s disease at the 24-month
follow up

conventional ratios thereof [47]. We then stratified the
patients into groups with and without pathological
CSF AD biomarker levels (Fig. 6). Cutoffs were determined by comparing AD biomarker levels between
cognitively healthy controls and AD patients at baseline.
The resulting ROC axes were labeled as sensitivity and

1-specificity; the accompanying results table provided the
individual cutoff values, sensitivity, specificity, and the
area under the curve (AUC) with its respective 95% confidence interval (95% CI) (Fig. 6). The cutoff values (Fig. 6)
for each CSF biomarker were then used to compare CSF
αSyn levels between CSF AD biomarker negative (CSF(−))

Table 2 Longitudinal cohort CSF αSyn correlation analysesǂ
Time

Longitudinal diagnosis

MMSE

CSF
Aβ1-42

CSF
Aβ1-40

CSF
Aβ42/40

CSF
t-tau

CSF
p-tau

Baseline

Control
(n=57)

-

(n=41)

0.616***
(n=37)

-0.542***
(n=37)

0.871***
(n=42)

0.766***
(n=42)

MCI-MCI
(n=27)

-

-

0.472**
(n=26)

(n=26)

0.577***

0.651***

MCI-AD
(n=27)

-0.605***

-

0.640***
(n=23)

-0.457*
(n=23)

0.736***

0.694***

AD
(n=27)

-

-

0.758***
(n=26)

(n=26)

0.722***

0.738***

MCI-MCI
(n=27)

-

(n=15)

0.703***
(n=15)

-0.575*
(n=15)

0.804***
(n=15)

0.849***
(n=15)

MCI-AD
(n=25)

-

(n=19)

0.863***
(n=18)

-0.732***
(n=18)

0.913***
(n=19)

0.927***
(n=19)

AD
(n=24)

-

(n=18)

0.691***
(n=18)

(n=18)

0.804***
(n=18)

0.770***
(n=18)

MCI-MCI
(n=24)

-

(n=14)

0.925***
(n=14)

(n=14)

0.782***
(n=14)

0.924***
(n=14)

MCI-AD
(n=24)

-

(n=18)

0.716***
(n=17)

-0.556*
(n=17)

0.902***
(n=18)

0.919***
(n=18)

AD
(n=18)

-

0.662**
(n=16)

0.585*
(n=16)

(n=16)

0.741**
(n=16)

0.650**
(n=16)

12-months

24-months

ǂ
All correlations calculated using the Spearman’s rank correlation test
MCI-MCI= MCI patients who remained MCI at the 24-month follow up
MCI-AD= MCI patients who converted to Alzheimer’s disease at the 24-month follow up
AD patients diagnosed with Alzheimer’s disease at baseline, MMSE Mini-Mental State Examination score
*p ≤0.05, **p ≤0.01, ***p ≤0.001
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Aβ42/40, t-tau, and p-tau between ADAD mutation carriers
and non-mutation carriers (Table 3). When the three ADAD
mutation carrier groups where subdivided into symptomatic
(CDR ≥ 0.5) and asymptomatic (CDR < 0.5) individuals
it was found that age of examination, EYO and MMSE
scores as well as CSF Aβ42/40 and CSF levels of t-tau,
and p-tau significantly differed between symptomatic
versus asymptomatic in APP mutation carriers (Table
3). Age of examination, EYO, MMSE and CDR scores,
CSF Aβ42/40, Aβ1–42, t-tau, and p-tau significantly differed between symptomatic and asymptomatic PSEN1
mutation carriers, while no differences could be observed
in the PSEN2 mutation carriers due to insufficient sample
size (Table 3).
Cerebrospinal fluid αSyn levels in ADAD mutation carriers
are related to onset of cognitive symptoms

Fig. 6 Receiver operator characteristic (ROC) curves of AD CSF biomarkers.
For each CSF biomarker analyte or ratio the table indicates the cutoff value,
sensitivity (%), specificity (%), and area under the ROC curve (AUC) with the
corresponding 95% confidence interval. A clinical diagnosis of healthy
control versus AD was used as the dichotomous variable to define CSF
cutoffs based on the best performing Youden index

and positive (CSF(+)) subjects within the diagnostic groups
(Fig. 7). When utilizing the cutoffs for CSF t-tau (>
470 pg/mL) and p-tau (> 71.6 pg/mL) in the MCI
and AD patients, we discovered significant differences
where CSF(+) patients had elevated αSyn compared to
CSF(−) patients (Fig. 7e-f). Additionally, the CSF p-tau/
Aβ42 cutoff (> 0.126) applied in the AD patient group
showed that the CSF(+) group had higher CSF αSyn than
the CSF(−) group (Fig. 7c).
Descriptive statistics of DIAN participants

In the ADAD mutation carrying participants from the
DIAN study, n = 6 APP, n = 33 PSEN1 and n = 3 PSEN2 mutations were represented (data not shown). Of the n = 92 included ADAD mutation carriers 34.8% had cognitive
symptoms (CDR ≥0.5). Specifically, 37.5% of APP, 42.0% of
PSEN1 and 11.1% of PSEN2 mutation carriers were symptomatic (Table 3). More than half of the PSEN2 mutation
carriers carried the APOEε4 allele, whereas a quarter of the
APP mutation carriers and less than 20% of the PSEN1
mutation carriers were APOEε4 carriers (Table 3). In all
three ADAD mutation groups, there was a higher percentage of APOEε4 carriers amongst the symptomatic mutation
carriers (p < 0.01). Further, we found significant variability in
the EYO, MMSE and CDR scores, and CSF levels of Aβ1–42,

After pooling all individual gene mutations into their respective groups (APP, PSEN1 and PSEN2 mutation carriers)
we compared the CSF αSyn levels between the three groups
and found no significant differences between the groups of
ADAD mutation carriers or versus non-mutation carriers
(Fig. 8a). Upon subdividing the ADAD mutation carriers
into either asymptomatic or symptomatic individuals we
found that symptomatic mutation carriers had higher CSF
αSyn compared to non-mutation carriers (Fig. 8b); no
further differences were found when APOEε4 status was included as a covariate (data not shown). Importantly, the
temporal trajectory of CSF αSyn versus EYO showed a
weak-to-moderate increase in both ADAD mutation carriers
(Pearson’s R = 0.20; p = 0.056) and in non-carriers (Pearson’s
R = 0.31; p = 0.032), where the confidence bands around
both trajectories showed a substantial overlap (Fig. 8c).
Cerebrospinal fluid αSyn and AD biomarker associations
in the DIAN cohort

To assess links between CSF αSyn levels and AD brain
pathology using surrogate CSF AD biomarkers in the
DIAN participants we investigated potential correlations
between CSF αSyn and CSF levels of Aβ1–42, Aβ1–40,
Aβ42/40, t-tau, and p-tau in ADAD non-mutation carriers
and the three ADAD mutation carrier groups sorted into
asymptomatic and symptomatic subgroups (the n = 2
PSEN1 symptomatic patient group was excluded from analysis) (Table 4). We found no correlations between CSF
αSyn and Aβ1–42 when combining asymptomatic and
symptomatic ADAD mutation carriers, but did find a positive correlation between CSF αSyn and Aβ1–40 in
non-mutation carriers, and both asymptomatic and symptomatic APP and PSEN1 mutation carriers. Inverse correlations between CSF αSyn and Aβ42/40 were found in
symptomatic APP and PSEN1 mutation carriers, but most
notably in the symptomatic APP mutation carrier group
(Table 4). There were strong positive associations between

Twohig et al. Acta Neuropathologica Communications

(2018) 6:130

Page 11 of 19

a

b

c

d

e

f

Fig. 7 Baseline levels of CSF αSyn in the longitudinal cohort based on ROC cutoff values. a-f Clinically diagnosed subjects subdivided into either
CSF Alzheimer’s disease (AD) biomarker negative (CSF(−)) or positive (CSF(+)) groups based on cutoff values. P-values were calculated using the
one-way ANCOVA of log-transformed data, with age entered as a covariate with post-hoc testing by use of the student’s t-test. Results are
displayed without log-transformation

CSF αSyn and t-tau in ADAD non-mutation carriers and in
all three mutation carrier groups, both asymptomatic and
symptomatic, with the strongest correlations found in
asymptomatic PSEN1 and symptomatic APP mutation carriers (Table 4). Asymptomatic PSEN1 mutation carriers also
exhibited a significant positive relationship between CSF
αSyn and p-tau while both non-mutation carriers and
PSEN2 mutation carriers demonstrated a significant positive correlation between CSF αSyn and p-tau levels.
Associations between brain Aβ plaque load and CSF αSyn
in the DIAN cohort

Data from PiB-PET examinations reflecting in vivo amyloid
plaque burden were available for n = 132 of the DIAN participants (dataset freeze 10). The frequency of PiB-positive
((SUVR/brainstem) ≥0.72) subjects was; 49.1% (28/57) of

asymptomatic mutation carriers, 89.3% (25/28) of symptomatic mutation carriers, and 4.3% (2/47) of non-mutation
carriers. As expected, PiB-retention increased with EYO in
mutation carriers, while no significant increase was noted
in non-mutation carriers (data not shown).
Potential associations between CSF αSyn levels and in
vivo amyloid plaque burden in subjects from the DIAN
cohort were investigated by analyzing the linear regressions of mean cortical PiB-retention versus CSF αSyn in
ADAD mutation carriers and non-mutation carriers separately, as well as stratifying mutation carriers into
asymptomatic and symptomatic groups, adding EYO as
independent predictor in all regression models; these
four models resulted in no significant associations between mean cortical PiB and αSyn (Table 5). When looking at the subset of PiB-positive asymptomatic ADAD

36

858 ±264

8173 ± 2751

0.115 ± 0.045

56 ± 26
(n = 49)

29 ± 14
(n = 49)

CDR

APOEε4 carrier (%)

CSF Aβ1–42 (pg/mL)

CSF Aβ1–40 (pg/mL)

CSF Aβ42/40

CSF t-tau (pg/mL)

CSF p-tau (pg/mL)

54 ± 34
(n = 89)

106 ± 73
(n = 87)

0.092 ± 0.052
(n = 89)

7477 ± 3146
(n = 89)

613 ± 320
(n = 89)

27

0.3 ± 0.6

27 ± 5

Sym

46 ± 25
(n = 23)

90 ± 64
(n = 23)

0.106 ± 0.065
(n = 23)

6639 ± 3278
(n = 23)

613 ± 353
(n = 23)

25

0.3 ± 0.5

27 ± 5

5 ± 11

42 ± 11

63/37

32 ± 11
(n = 14)

60 ± 30
(n = 14)

0.128 ± 0.066
(n = 14)

6302 ± 3494
(n = 14)

734 ± 393
(n = 14)

20

0±0

29 ± 1

−11 ± 11

39 ± 12

67/33

69 ± 24

137 ± 76

0.072 ± 0.049

7162 ± 3033

425 ± 164

33

1 ± 0.5

23 ± 7

4±3

49 ± 6

56/44

9

60 ± 37
(n = 49)

124 ± 82
(n = 47)

0.088 ± 0.048
(n = 49)

7563 ± 2785
(n = 49)

621 ± 335
(n = 49)

18

0.4 ± 0.7

26 ± 6

−6 ± 12

39 ± 10

60/40

50

45 ± 28
(n = 28)

94 ± 56
(n = 26)

0.102 ± 0.047
(n = 28)

8313 ± 2918
(n = 28)

770 ± 318
(n = 28)

14

0±0

29 ± 1

−14 ± 10

34 ± 9

52/48

29

Asym

All

15

Asym

All
24

PSEN1
Mutation Carriers

APP
Mutation Carriers
Sym

81 ± 38

162 ± 94

0.070 ± 0.045

6563 ± 2300

422 ± 243

24

1 ± 0.8

21 ± 7

5±4

46 ± 8

71/29

21

45 ± 31
(n = 17)

75 ± 39
(n = 17)

0.082 ± 0.037
(n = 17)

8363 ± 3810
(n = 17)

592 ± 233
(n = 17)

56

0.1 ± 0.5

29 ± 3

−13 ± 11

40 ± 10

33/66

18

All

48 ± 32
(n = 15)

72 ± 40
(n = 15)

0.076 ± 0.031
(n = 15)

8811 ± 3776
(n = 15)

596 ± 249
(n = 15)

50

0±0

30 ± 1

−15 ± 9

38 ± 9

32/68

16

Asym

PSEN2
Mutation Carriers

29

98

0.129

5005

565

100

1

20

7

57

50/50

2

Sym

-c

*c

-c

-c

-c

**e

-d

*c

–

***c

–

p-valuea

Asym = asymptomatic Sym = symptomatic EYO = estimated yeats from symptom onset MMSE = Mini-Mental State Exam scorre
CDR = Clinical Dementia Rating score a = p-value versus all mutation carriers c = Kruskal-Wallis test d = Mann-Whitney U test e = χ2 test § = non-normally distributed data presented at mean ± standard deviation in order
to maintain patient anonymity
- = non-significant * = p ≤ 0.05 ** = p ≤ 0.01 *** = p ≤ 0.001

0±0

MMSE§

−7 ± 12

−9 ± 11

29 ± 1

EYO

40 ± 10

40 ± 11

Age at
examination (yrs)

55/45

56/44

Sex (% f/m)

92

50

All Mutation
Carriers

N

Non-Mutation
Carriers

Table 3 DIAN cohort baseline characteristics
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Fig. 8 CSF αSyn levels quantified in participants from the DIAN cohort. a CSF αSyn levels grouped by ADAD gene mutation. b CSF αSyn in ADAD
non-mutation carriers versus asymptomatic and symptomatic ADAD mutation carriers. Data point coloring represents the three ADAD genes as shown
in (a). P-values are presented first as uncorrected followed by Bonferroni corrected (a-b: n = 3 comparisons). P-values calculated using the nonparametric Kruskal-Wallis test and a Bonferroni correction was used to account for multiple comparisons. c Correlation between CSF αSyn and the
estimated years from symptom onset (EYO) in ADAD mutation carriers and non-mutation carriers; correlations are calculated using Pearson’s
correlation test after log-transformation of the CSF αSyn data and results are displayed without log-transformation or age-correction (raw data)

mutation carriers, however, the same linear regression
model showed a significant positive association between mean cortical PiB and αSyn (β = 0.44, p =
0.010); results from exploratory linear regression models
in 42 regions of interest in PiB-positive asymptomatic mutation carriers are illustrated in Fig. 9a in which the regional regression β coefficients are displayed on a 3D
brain surface. The strongest associations between CSF
αSyn and amyloid plaque load in PiB-positive asymptomatic ADAD mutation carriers were found in regions including the posterior cingulate, superior temporal and
frontal (Fig. 9a).
A potential effect of APOEε4 on the association between
PiB and αSyn in ADAD mutation carriers was assessed by
the linear regression model: Mean cortical PiB ~ αSyn +
APOEε4 + EYO + αSyn*APOEε4, and results are presented
on Table 5. The interaction of αSyn*APOEε4 was significant,
indicating that the relationship between PiB-retention and
αSyn is different in APOEε4-positive than in APOEε4-negative ADAD mutation carriers. In APOEε4-positive ADAD
mutation carriers, there was a strong positive association between αSyn and mean cortical PiB (β = 0.39, p = 0.032)
(Table 5), while this association was not significant in

APOEε4-negative mutation carriers (β = − 0.10, p = 0.348)
(data not shown). Exploratory positive associations between
αSyn and regional PiB in APOEε4-positive ADAD mutation
carriers in the 42 regions of interest are illustrated on the
3D brain display, showing strong associations in regions including the superior temporal, anterior and posterior cingulate, parietal and frontal regions (Fig. 9b). The CSF
αSyn-APOEε4-PiB relationship was specific and could not
be replicated by replacing CSF αSyn with CSF t-tau levels
(data not shown).
The positive significant associations between CSF αSyn
and regional amyloid plaque load in PiB-positive asymptomatic ADAD mutation carriers are illustrated in Fig. 10 in regions of early amyloid plaque deposition within the frontal
and temporal lobes (Fig. 10a-b), contrasting with respective
negative associations observed in few regions in the symptomatic mutation carriers, mostly restricted to areas of late
amyloid plaque deposition including paracentral and postcentral regions (Fig. 10c-d).

Discussion
The role of αSyn in the context of AD pathophysiology
is unknown. In this study we set out to investigate the

Table 4 DIAN cohort CSF αSyn correlation analysesa
Non- mutation
carriers

APP mutation carriers

PSEN1 mutation carriers

PSEN2 mutation carriers

Asym
(n = 15)

Sym
(n = 9)

Asym
(n = 29)

Sym
(n = 21)

Asym
(n = 16)

Sym
(n = 2)

CSF Aβ1–42

0.595***

–

–

–

–

–

¤

CSF Aβ1–40

0.744***

0.610*

0.717*

0.526**

0.788***

–

¤

CSF Aβ42/40

–

–

−0.800**

–

−0.464*

–

¤

CSF t-tau

0.716***

0.676*

0.917***

0.943***

0.664***

0.736**

¤

CSF p-tau

0.544***

–

–

0.809***

0.662***

–

¤

a

= All correlations calculated using the Spearman’s rank correlation test
Asym = asymptomatic Sym = symptomatic
¤ = not determined * = p ≤ 0.05 ** = p ≤ 0.01 *** = p ≤ 0.001
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Table 5 Linear regression models relating mean cortical 11CPittsburgh Compound-B uptake and αSyn in ADAD mutation
carriers
Model (PiB-positive asymptomatic mutation carriers): Mean cortical PiB ~
αSyn + EYO
Standardized β

Std. Error

t value

p value

αSyn

0.375

0.00047

2.348

0.027

EYO

0.444

0.00676

2.780

0.010

Independent predictors

Model (all mutation carriers): Mean cortical PiB ~ αSyn + APOEε4 + EYO
+ αSyn*APOEε4
Estimate

Std. Error

t value

p value

αSyn

−0.00038

0.00039

−0.970

0.335

APOEε4

−0.98698

0.44767

−2.205

0.030

Independent predictors

EYO

0.02682

0.00435

6.164

0.000

αSyn*APOEε4

0.00244

0.00099

2.468

0.016

Model (APOEε4-positive mutation carriers): Mean cortical PiB ~ αSyn + EYO
Standardized β

Std. Error

t value

p value

αSyn

0.393

0.00088

2.321

0.032

EYO

0.533

0.00864

3.147

0.005

Independent predictors

PiB = 11C-Pittsburgh Compound-B EYO = estimated years from symptom onset

Fig. 9 Brain maps depicting significant associations between CSF αSyn
and PiB-retention in ADAD mutation carrier subgroups. a PiB-positive
asymptomatic (CDR < 0.5), b APOEε4-positive (CDR < 0.5). The significant
associations between CSF αSyn and PiB are represented by the
standardized β coefficient corresponding to independent predictor αSyn
in the linear regression model for PiB ~ αSyn + EYO, where EYO is
estimated years from symptom onset. Increasing positive associations
(increasing β values) are labeled from red to yellow
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relevance of αSyn to both sporadic and familial AD by
examining CSF levels of αSyn and potential associations
to various AD disease parameters including cognition,
CSF AD biomarkers, and in familial AD patients we also
assessed potential relationships between CSF αSyn and
brain amyloid plaque burden. Although the significance
of CSF αSyn levels to brain parenchymal αSyn levels are
still unknown, mainly due to the lack of ante-mortem
αSyn brain imaging tools, we anticipate that CSF αSyn
fluctuations mirror αSyn alterations in the brain. We
studied subjects with MCI, sporadic AD and ADAD in
order to pinpoint any potential pre-clinical, prodromal,
or mid- to late stage disease pathways linking αSyn to
AD pathogenesis. We further explored the impact of the
AD risk allele APOEε4 on the identified associations.
Numerous studies have reported αSyn pathology in approximately 50–60% of autopsied AD patients [1, 16, 31].
Patients with mixed pathologies as well as animal models
expressing combined AD and αSyn pathologies tend to
exhibit amplified deterioration, typically enduring more
severe symptoms and shorter survival rates [9, 41]. Interestingly, Wirths and colleagues described co-accumulation of
αSyn in Aβ plaques and dystrophic neurites only in patients
with the Lewy body variant of AD rather than in ‘typical
AD’ cases [65]. Furthermore, results from another study of
147 neuropathologically confirmed AD cases suggested that
the majority of AD patients who exhibited very few or no
neocortical neurofibrillary tangles, termed ‘plaque-only AD’,
exhibited Lewy body αSyn pathology, while patients with
the Lewy body variant of AD were found to be ‘plaque-only
AD’ cases, hence, ‘plaque-only AD’ and Lewy body variant
AD were diagnostically indistingushable from one another
[17]. Currently, the mechanisms driving comorbid αSyn
and AD pathologies have yet to be elucidated making it impossible to predict comorbidity or to diagnose patients
ante-mortem, however, we speculate that altered CSF αSyn
may be a predictive feature of AD patients that already are
harboring or that will develop αSyn co-pathology.
The identification of a molecular interaction between
presenilin 1 (PS1), encoded by the PSEN1 gene, and
αSyn was suggested to in part explain the clinical and
pathophysiological overlaps between AD and synucleinopathies like DLB [64]. The relevance of this molecular
interaction was illustrated by two previous reports demonstrating a strong association between ADAD-causing
PSEN1 mutations and Lewy body pathology specifically
in the amygdala [29, 31]. With a direct interaction between αSyn and PS1, the latter of which is a key player
in Aβ peptide production [8], it is tempting to speculate
that αSyn may have a modulatory role in Aβ production
and/or deposition. In support, our current study revealed an association between higher CSF αSyn levels
and amyloid plaque burden in several brain areas of
PiB-positive asymptomatic ADAD mutation carriers.
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Fig. 10 Significant associations between CSF αSyn and regional PiB-retention in PiB-positive asymptomatic (CDR < 0.5, n = 28) ADAD mutation
carriers (blue) and in symptomatic (CDR ≥0.5, n = 25) ADAD mutation carriers (purple) . The significant associations between CSF αSyn and PiB are
represented by the standardized β coefficient corresponding to independent predictor αSyn in the linear regression model for PiB ~ αSyn + EYO,
where EYO is estimated years from symptom onset, in four brain regions (a-d)

The brain regions exhibiting the highest rates of annual
Aβ accumulation in PiB-negative (< 0.87 SUVR) individuals with pathological CSF Aβ1–42 levels (< 192 ng/L),
termed as ‘early Aβ accumulators’ by Palmqvist and colleagues in a recent publication [44], exhibited a striking
overlap with the brain regions for which we found significant positive correlations between CSF αSyn and
PiB-retention. Similarly, a recent study of cognitively
normal individuals with subjective memory complaints
documented a positive association between CSF αSyn concentrations and brain Aβ deposition [59]. Rather surprisingly, our identified relationship between CSF αSyn levels
and Aβ deposition in presymptomatic ADAD patients was
not paralleled by any significant correlations between CSF
αSyn and Aβ1–42 levels. Instead, CSF αSyn levels were consistently positively associated with CSF Aβ1–40 levels levels
across all studied groups. The relevance of CSF Aβ1–40 in
the presymptomatic stage of AD, during which Aβ deposition occurs, remains to be determined.

In support of our own results [61, 62] and those reported by other groups [60] we further identified strong
positive correlations between CSF αSyn and CSF t-tau and
p-tau in both studied cohorts. By stratifying the studied
sporadic MCI and AD patients based on pathological CSF
AD biomarker levels, we found elevated CSF αSyn levels
in patients that exhibited pathological CSF tau but not Aβ
levels. Similar to CSF levels of tau, CSF αSyn levels were
previously proposed to potentially function as a marker of
synapse loss and neurodegeneration [43], however the lack
of significantly altered levels of CSF αSyn in AD does not
support this notion. A direct link between αSyn and tau
pathology was instead suggested by findings showing that
αSyn promotes GSK-3β-mediated tau phosphorylation
[25]. The authors of the same study further demonstrated
that αSyn directly interacted with both tau and GSK-3β.
Another in vitro study employing rat PC12 cells demonstrated that extracellular αSyn in fact was involved in
GSK-3β-mediated hyperphosphorylation of tau [15]. In
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cognitively intact control subjects we found strong positive correlations between levels of CSF αSyn and both
t-tau and p-tau, which in our view may challenge the notion that the relationship between αSyn and tau is indeed
pathological. Due to our findings of a consistent correlation between CSF αSyn and tau levels across diagnostic
groups including healthy controls, we speculate that the
this association might be due to non-conventional
exosome-related release mechanisms [12, 51] for both tau
and αSyn, without any clear disease association. The exact
relevance of the described seemingly robust relationship
between levels of CSF tau and αSyn requires clarification,
preferably in future studies assessing potential links between CSF αSyn and ante-mortem tau pathology using
novel tau tracers and imaging techniques [50].
With the APOEε4 allele as a common denominator in
terms or risk of disease for both AD and DLB [7] we
were interested in assessing potential effects of this gene
variant on CSF αSyn levels in the investigated cohorts.
In subjects from the MCI-AD diagnostic group who exhibited elevated CSF αSyn levels compared to controls
at baseline, homozygous APOEε4 carriers exhibited the
highest CSF αSyn levels. This observation was absent in
AD patients and control subjects. Hence, we observed
an effect of the APOEε4 variant on CSF αSyn levels in the
prodromal phase of sporadic AD, but no effect once patients were clinically diagnosed with AD. When considering any effect of the APOEε4 allele in ADAD mutation
carrying DIAN participants, we found no differences in
CSF αSyn between APOEε4 positive versus APOEε4
negative participants, or within the APP, PSEN1 or PSEN2
mutation carrying groups. However, presymptomatic Aβ
deposition in ADAD mutation carriers was positively
associated with CSF αSyn levels only in APOEε4 positive
subjects. We hypothesize that an association between CSF
αSyn and Aβ deposition at the presymptomatic stage of
AD may be further supported by the APOEε4 variant
which in previous studies has been shown to promote Aβ
deposition even in cognitively intact individuals [40].
The regulatory mechanisms governing αSyn levels in
brain parenchyma and CSF are unknown. However,
there is a clear difference between CSF αSyn levels in
AD patients and those with synucleinopathies, where patients afflicted with the latter disorders consistently exhibit reduced levels [18, 24, 38, 39, 56, 57] suggesting a
disease-specific process that disrupts the balance between the intracellular and extracellular pools of αSyn.
Kallikrein-6, also called neurosin, is one of few reported
extracellular proteases shown to cleave αSyn [52, 55]. Increasing the expression of kallikrein-6 in the brains of a
mouse model of Lewy body disease promoted αSyn
clearance and reduced αSyn pathology [52]. Further, we
have shown that patients with synucleinopathies not
only exhibited low CSF αSyn levels but also reduced
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levels of kallikrein-6 [62]. Thus, our previous results
combined with those from animal studies suggest that
an imbalance between αSyn and kallikrein-6 may promote synucleinopathy. Recently we also reported that
the AD and MCI-AD patients examined in the current
study did not exhibit altered levels of CSF kallikrein-6
compared to controls, whereas MCI-MCI patients had
slightly lower CSF kallikrein-6 levels compared to controls [45]. Hence, the elevated CSF αSyn levels observed
in the MCI-AD group were not paralleled by increased
kallikrein-6 levels suggesting a potential imbalance
between kallikrein-6 and αSyn in this group.
We conclude, CSF αSyn levels alone appear unfit to
serve as a diagnostic marker for AD however higher CSF
αSyn concentrations were associated with the progression
from MCI to sporadic AD, and with the development of
symptoms in subjects carrying ADAD mutations. Although not paralleled by significant correlations with CSF
Aβ1–42, higher levels of CSF αSyn in the presymptomatic
stages of ADAD were associated with Aβ plaque burden
in several brain regions known to accumulate Aβ pathology during early stages of AD development. The presence of an APOEε4 allele in sporadic AD cases appeared
to promote higher CSF αSyn levels which may accelerate
the processes linking αSyn to Aβ deposition in AD. The
APOEε4 allele may be involved in molecular processes
governing CSF αSyn levels, which in turn appear associated with the presymptomatic build-up of Aβ plaque burden in the brain during AD development. Future studies
assessing αSyn in paired CSF and autopsied brain tissues
are needed in order to decipher the relevance of altered
CSF αSyn levels in the pathophysiology of AD.
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